Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

NCT03125200 PHASE1 TERMINATED Results posted

This study evaluated ADCT-502 in participants with Advanced Solid Tumors with HER2 Expression. Participants participated in a dose-escalation phase (Part 1) and were due to participate in the dose expansion phase (Part 2). In Part 2, patients were due to receive the dose level identified in Part 1, but the study was terminated prior to the beginning of Part 2.

Details

Lead sponsor	ADC Therapeutics S.A.
Phase	PHASE1
Status	TERMINATED
Enrolment	21
Start date	Thu May 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Apr 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Breast Cancer
• Non Small Cell Lung Cancer
• GastroEsophageal Cancer
• Bladder Cancer

Interventions

• ADCT-502

Countries

Belgium, United States